Back to search

Peptide record

TPDB43195

LCP-3 Anticancer standard
4 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB43195
LCP-3
Anticancer
Cancer-related peptides
CancerPPD 2.0
standard
No
A 4-aa standard natural anticancer peptide sequence curated from CancerPPD 2.0, with an available 3D structural model.
C-terminal: Cyclized N-terminal: Cyclized
Sequence
WHLV
Physicochemical Analysis
C28H39N7O5
ARNDCEQGIKMFPSTY
HLWV
553.66
7.85
1
0
3
+0
-1.38
0.975
170.00
Mammalian: 2.8 hour Yeast: 3 min E.coli: 2 min
5500
993.39
0
Residue Composition
number
0
A
0
R
0
N
0
D
0
C
0
E
0
Q
0
G
1
H
0
I
1
L
0
K
0
M
0
F
0
P
0
S
0
T
1
W
0
Y
1
V
Amino Acid Distribution
A: 0 R: 0 N: 0 D: 0 C: 0 E: 0 Q: 0 G: 0 H: 1 I: 0 L: 1 K: 0 M: 0 F: 0 P: 0 S: 0 T: 0 W: 1 Y: 0 V: 1
Chemical Descriptors
4
C28H39N7O5
553.66
7.85
+0
-1.38
0.975
Cyclized
L
Cyclic
Cyclized
Anticancer
Laminaria japonica
Evidence Records 4 records
Evidence 1 Activity

Activity

IC50
IC50 = 101 ± 10.6 µM
Anticancer
101

Target

Gastric Cancer
SGC-7901
Stomach

Assay & Model

MTT assay
48-h

Source & Reference

CancerPPD 2.0
CancerPPD2
2021

Other

Source Activity Label Source Definition
Anticancer
CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation.
Evidence 2 Activity

Activity

IC50
IC50 = 86.9 ± 9.11 µM
Anticancer
86.9

Target

Gastric Cancer
MKN-45
Stomach

Assay & Model

MTT assay
48-h

Source & Reference

CancerPPD 2.0
CancerPPD2
2021
Evidence 3 Activity

Activity

IC50
IC50 = 85.2 ± 9.27 µM
Anticancer
85.2

Target

Gastric Cancer
HepG-2
Stomach

Assay & Model

MTT assay
48-h

Source & Reference

CancerPPD 2.0
CancerPPD2
2021
Evidence 4 Activity

Activity

IC50
IC50 = 68.2 ± 7.11 µM
Anticancer
68.2

Target

Colon Cancer
CaCo-2
Colon

Assay & Model

MTT assay
48-h

Source & Reference

CancerPPD 2.0
CancerPPD2
2021